Servei de Medicina Interna-Hepatología, Hospital Vall d'Hebron, Madrid, Spain.
Curr Opin Crit Care. 2011 Apr;17(2):177-83. doi: 10.1097/MCC.0b013e328344b37e.
Brain disturbances, which are considered a form of hepatic encephalopathy, are common in acute-on-chronic liver failure.
Patients with hepatic encephalopathy exhibit sings of energy impairment that may participate in the development of disturbances in neurotransmission. Ammonia participates in the genesis of brain edema and in the development of oxidative stress injury to astrocytes. Neuroinflammation is a new element that has been described in experimental models. These mechanisms are involved in the genesis of cognitive sequels that may persist after liver transplantation. Clinical trials have demonstrated the value of drugs that decrease the production of ammonia in the intestines to prevent encephalopathy. In addition, improvement of circulatory dysfunction with the use of albumin and vasoconstrictors may prevent hepatic encephalopathy in acute-on-chronic liver failure. New drugs that act by enhancing ammonia disposal through the synthesis of nitrogenous metabolites have shown promising results.
A better knowledge of the pathogenesis of brain disturbances in acute-on-chronic liver failure provides the rationale for using ammonia-focused therapy in the prevention and treatment of encephalopathy. New therapies addressed to correct brain edema, circulatory dysfunction and inflammation may also be useful for encephalopathy and may improve the neurological outcome.
在慢加急性肝衰竭中,脑功能障碍被认为是肝性脑病的一种形式,较为常见。
肝性脑病患者表现出能量损伤的迹象,这可能参与了神经传递障碍的发生。氨参与脑水肿的发生和星形胶质细胞氧化应激损伤的发展。神经炎症是在实验模型中描述的一个新元素。这些机制与肝移植后可能持续存在的认知后遗症的发生有关。临床试验已经证明了降低肠道氨生成的药物在预防脑病方面的价值。此外,通过使用白蛋白和血管收缩剂改善循环功能障碍也可能预防慢加急性肝衰竭中的肝性脑病。通过合成含氮代谢物增强氨处理的新型药物已显示出良好的效果。
对慢加急性肝衰竭中脑功能障碍发病机制的更好认识为氨靶向治疗在预防和治疗脑病中的应用提供了依据。针对纠正脑水肿、循环功能障碍和炎症的新疗法也可能对脑病有用,并可能改善神经预后。